#patent cliff
3 stories
AbbVie Dividend King Standout?
AbbVie's 54-year dividend streak and patent resilience make it a top pick for income-focused investors despite industry risks.
Yahoo Finance · 1m
Novo Nordisk Stock Drops 7% After Growth Plan Fails to Ease Competition Fears
Novo Nordisk's stock falls 7% as its post-Wegovy growth plan fails to reassure investors about competition risks
24/7 Wall St. · 1m
Amgen vs Merck: which dividend keeps growing?
Two pharma giants both raise dividends yearly, but only one has the portfolio depth to survive the next patent cliff.
24/7 Wall St. · 1m